Delaware Court Denies Dismissal in $9B Deal Challenge
The ruling creates new litigation risks for boards involving investor-driven conflict-of-interest protections.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Should large corporations be allowed to restrict legal challenges to their acquisition deals?
A Delaware judge has denied a motion to dismiss a lawsuit challenging the $9 billion acquisition of R1 RCM Inc. by an affiliate of TowerBrook Capital Partners LP and Ascension Health Alliance. This decision marks the first judicial interpretation of specific sections of Delaware's 2025 corporate overhaul regarding insider conflicts of interest.
Why it matters
The ruling creates legal uncertainty for businesses operating under Delaware corporate law by limiting the effectiveness of new safe harbor protections in deals involving majority-nominating investors. It signifies that board-level protections are subject to rigorous judicial scrutiny despite legislative efforts to streamline dealmaking.
The litigation concerns a $9 billion acquisition involving R1 RCM Inc. and its investors, representing a significant test of the state's new regulatory safe harbors. The case examines the influence of an entity capable of nominating a majority of the board.
The players
R1 RCM Inc.
A revenue cycle management provider serving healthcare systems, now at the center of a major acquisition challenge.
J. Travis Laster
A Vice Chancellor of the Delaware Court of Chancery known for presiding over significant corporate governance litigation.
TowerBrook Capital Partners LP
An investment firm and private equity manager involved in the acquisition through an affiliate.
Ascension Health Alliance
A large nonprofit Catholic health system that is a partner in the acquisition entity.
The details
Vice Chancellor J. Travis Laster allowed a group of funds to move forward with their legal challenge, rejecting the defendants' arguments based on the state's new conflict-of-interest safe harbors. The ruling specifically addresses how courts now assess potential insider conflicts during high-stakes corporate transactions. Operators should note that the court is closely reviewing how control is exercised when entities have the power to nominate a majority of a company's board of directors.
Timeline
The Delaware corporate overhaul was enacted in 2025.
The court issued the ruling on October 28, 2026.
Market Landscape
This case marks the first major judicial test of Delaware's 2025 corporate overhaul. It follows a legislative attempt to expand dealmaking safe harbors, but now signals that judicial scrutiny over insider conflicts remains robust.
Business owners must account for the reality that Delaware's new safe harbors do not guarantee immunity from litigation in conflict-of-interest scenarios. Governance teams should review board nomination structures to ensure they can withstand rigorous legal scrutiny regarding control dynamics.
The takeaway
The court's decision underscores that established fiduciary obligations in Delaware still carry significant weight in the face of new corporate legislation. Operators should monitor this case for evolving standards on how board control and investor influence affect the validity of major corporate deals.
Further reading
For broader context on current industry shifts, see Healthcare.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Should large corporations be allowed to restrict legal challenges to their acquisition deals?
